AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Algeta ASA - Interim data from Phase II clinical study of Alpharadin as a treatment for bone metastases in prostate cancer patients to be presented at 2006 Prostate Cancer Symposium.
(From Hugin)
Oslo, Norway, February 10, 2005 - Algeta ASA is pleased to announce that an abstract relating to interim clinical data from a Phase II trial of its lead product Alpharadin (Radium-223) has been accepted for presentation at the 2006 Prostate Cancer Symposium in San Francisco, CA, February 24-26, 2006. A poster discussing the interim results will be presented in General Poster Session E between 11.30 and 13.00 on February 26, 2006. Alpharadin is a novel bone-seeking radiopharmaceutical currently in Phase II trials as a potential new treatment for bone metastases in prostate cancer patients. The present trial (BC1-02) was initiated to study the therapeutic …
-
- Algeta ASA raises EUR 23 M in Series A round.
-
News wire article from: Asia Africa Intelligence Wire
September 2, 2005
700+ words
-
- Algeta ASA raises Euro 23 million in Series A round.
-
News wire article from: Europe Intelligence Wire
September 2, 2005
700+ words
-
- Algeta ASA - Notice of Extra Ordinary General Meeting.
-
News wire article from: Europe Intelligence Wire
August 28, 2008
700+ words
-
- Algeta ASA - Notice of Annual General Meeting 2009.
-
News wire article from: Europe Intelligence Wire
April 30, 2009
700+ words
-
- Algeta ASA - extends deadline for AGM attendance and proxies to 13 May 16:00.
-
News wire article from: Europe Intelligence Wire
May 11, 2009
700+ words
